Clinical trials: Hyperbilirubinemia, Neonatal
Jaundice, Neonatal
A mHealth Application as a Screening Tool for Neonatal Jaundice in Filipino Neonates
The purpose of the study is to test the reliability of the Picterus smartphone application in Filipino neonates. A descriptive cross-sectional study will be the method to understand the correlation of the modalities and to…
- Trial name
- NCT05616845
- Testing
- Picterus Jaundice Pro
- Where
- Philippines
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Picterus AS
Neonatal Jaundice
Clinical Validation of the Screening Tool Picterus JP Using Different Smartphones
The overall aim of this study is to verify the quality of our internal developed camera validation systems and allow the use of Picterus JP on all smartphones.
- Trial name
- allphones (NCT05955144)
- Testing
- Picterus JP
- Where
- Norway
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Picterus AS
Jaundice, Neonatal, Hyperbilirubinemia, Neonatal
Stannsoporfin With Light Therapy for Newborn Babies With Jaundice
It is normal for red blood cells to die, even in newborn babies. The waste from that is called bilirubin. The liver clears bilirubin out of the body.
- Trial name
- JASMINE_204 (NCT01887327)
- Testing
- Phototherapy, Stannsoporfin
- Where
- 18 sites in United States
- Volunteers
- 91 people
- Sponsor
- InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Neonatal Jaundice
Intermountain Inpatient Bilirubin Decision Accuracy Study Using Smartphone-based Measurements by Picterus Jaundice Pro
The goal of this project is to evaluate the performance of Picterus Jaundice Pro in an American population, including preterm and term newborns and pre- and post- phototherapy.
- Trial name
- NCT06329843
- Testing
- Picterus Jaundice Pro (JP)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Picterus AS
Urea Cycle Disorders, Crigler Najjar Syndrome
Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)
The purpose of this study is to assess the safety and to appraise the efficacy of one cycle of Hepastem (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC) infusions in paediatric patients suffering from CN or UCD.
- Trial name
- HEP001 (NCT01765283)
- Testing
- HepaStem
- Where
- 11 sites in Belgium, France and 3 more
- Volunteers
- 20 people
- Sponsor
- Cellaion SA
Hyperbilirubinemia, Neonatal
A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
It is a normal process in the human body for red blood cells to die, which makes bilirubin. Bilirubin is cleared away through the liver.
- Trial name
- NCT00850993
- Testing
- Stannsoporfin, PhotoTherapy (as needed)
- Where
- 23 sites in United States, Poland and 2 more
- Volunteers
- 58 people
- Sponsor
- InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Urea Cycle Disorders, Crigler Najjar Syndrome
Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)
The purpose of this study is to assess the long-term safety follow-up of patients having been treated with HepaStem.
- Trial name
- NCT02051049
- Where
- Belgium
- Volunteers
- 9 people
- Sponsor
- Cellaion SA
Meulengracht Syndrome, Hyperbilirubinemia
Biomarker for Gilbert Disease (BioGilbert)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Gilbert disease from blood
- Conditions
- Meulengracht Syndrome, Hyperbilirubinemia, Unconjugated Benign Bilirubinemia
- Trial name
- BioGilbert (NCT02712138)
- Where
- 4 sites in Egypt, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock